WKY Fatty Rat as a Model of Obesity and Non-insulin-dependent Diabetes Mellitus
Abstract
Health. Peterson, R. G., A. K. Sharma, L. A. Little, M. Neel, C. G. Potter, and J. Eichberg. 1988b. Peripheral nerve abnormalities in Wistar fatty diabetic rats. Pp. 488-491 in Frontiers in Diabetes Research. Lessons from Animal Diabetes II, E. Shafrir and A. E. Renold, eds. London: John Libbey. Seino, Y., S. Seino, M. Usami, K. Tsuda, J. Takemura, S. Nishi, H. Ishida, and H. Imura. 1984. Somatostatin, glucagon, and insulin secretion from isolated perfused pancreas of new genetically obese hyperglycemic rats. Metabolism 33(5):429-431. Sugiyama, Y., Y. Shimura, and H. Ikeda. 1989a. Pathogenesis of hyperglycemia in genetically obese-hyperglycemic rats, Wistar fatty: Presence of hepatic insulin resistance. Endocrinol. Japon. 36(1):6573. Sugiyama, Y., Y. Shimura, and H. Ikeda. 1989b. Derangement in hepatic enzymes caused by sucrose-drinking and its implication for the development of hyperglycemia in female Wistar fatty rats. Endocrinol. Japon. 36(2):245-251. Sussman, K. 1985. Spectrum of defects in non-insulin-dependent diabetes mellitus. Am. J. Med. 79 (suppl. 79): 1-5. Terrettaz, J., and B. Jeanrenaud. 1983. In vivo hepatic and peripheral insulin resistance in genetically obese (fa/fa) rats. Endocrinology 112:1346-1351. West, D. B., R. Rohlfing, R. Kava, and M. R. C. Greenwood. In press. Hepatic glucose production (HGP) is elevated in obese diabetic Wistar fatty (Wf) rats. Int. J. Obesity (abstr.). Zucker, L. M., and T. F. Zucker. 1961. Fatty, a new mutation in the rat. J.…
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.